Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".
clinical practice guideline
individual fitness score (IFS)
prescription
quality indicator
schizophrenia
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
24
08
2022
received:
16
07
2022
accepted:
30
08
2022
pubmed:
19
10
2022
medline:
24
12
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.
Identifiants
pubmed: 36254805
doi: 10.1002/npr2.12293
pmc: PMC9773743
doi:
Substances chimiques
Antipsychotic Agents
0
Banques de données
UMIN-CTR
['UMIN000022645']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-509Informations de copyright
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
World J Biol Psychiatry. 2012 Jul;13(5):318-78
pubmed: 22834451
BJPsych Open. 2022 Apr 21;8(3):e83
pubmed: 35446248
Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324
pubmed: 34390232
Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648
pubmed: 31437336
Sleep Med. 2022 Jan;89:23-30
pubmed: 34875519
Neuropsychopharmacol Rep. 2022 Mar;42(1):3-9
pubmed: 34854260
Neuropsychopharmacol Rep. 2021 Jun;41(2):199-206
pubmed: 33704931
Psychiatry Res. 2021 Mar;297:113764
pubmed: 33567393
Neuropsychopharmacol Rep. 2022 Dec;42(4):502-509
pubmed: 36254805
Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286
pubmed: 32602667
Asian J Psychiatr. 2022 Mar;69:103007
pubmed: 35051727
Asian J Psychiatr. 2021 Sep;63:102744
pubmed: 34325252
Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669
pubmed: 32881226
Can J Psychiatry. 2017 Sep;62(9):624-634
pubmed: 28886671
J Hepatobiliary Pancreat Sci. 2022 Oct;29(10):1057-1083
pubmed: 35388634
Med J Aust. 2017 Jun 19;206(11):501-505
pubmed: 28918734